Indian stocks: Visit www.stage2stocks.com →

Pulmonx Corporation

Stage 2 · Advancing · week 9

As of Oct 22, 2026, Pulmonx is in Stage 2, the uptrend phase, now in week 9 (since Aug 26, 2026). It closed at $1.88, 27.7% below its 52-week high and above its 200-day average, which is falling.

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. More about the company

$1.88
+2.73% today
$80.7M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care

Is LUNG early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 22w
S4 14w
S4 27w
S4 17w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 1w → S3 7w → S4 9w → S1 5w → S2 8w → S3 4w → S4 22w → S1 10w → S4 14w → S1 2w → S2 6w → S3 1w → S4 27w → S1 3w → S4 1w → S1 10w → S4 17w → S1 10w → S2 8w current
Total tracked: 165 weeks across 19 stage runs.

LUNG among Medical Devices35th of 141 by relative strength

All 141 →
Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#StockStageRS1M
1TXGStage 2 · wk 4899−7.8%
2RCELStage 2 · wk 1398+40.8%
3BFLYStage 2 · wk 2698−26.0%
4HAEStage 2 · wk 1796+8.7%
5GKOSStage 2 · wk 2596+15.1%
6AXGNStage 3 · wk 295−15.3%
7NEOGStage 2 · wk 1495−11.7%
8BVSStage 2 · wk 1595+10.5%
…35LUNGStage 2 · wk 967−6.0%
vs 52W High
-27.7%
$1.17 lo$2.60 hi
27.7% below 52W high, far from high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 9
1w13w26w
Week 9, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
14.3%
200 DMA: $1.65 · sloping down
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.40x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-6.0%
3M
+60.7%
6M
+46.9%
YTD
-18.3%
1Y
+16.8%
Scan Membership
Breakout Watch
Latest: 2025-03-07
3 appearances in last 60 days. First seen: 2023-05-30.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 9 · Vol 0.40x
2026-10-21S2
Wk 8 · Vol 0.50x
2026-10-20S2
Wk 8 · Vol 1.46x
2026-10-19S2
Wk 8 · Vol 0.60x
2026-10-16S2
Wk 8 · Vol 0.65x
2026-10-15S2
Wk 8 · Vol 0.70x
2026-10-14S2
Wk 7 · Vol 0.72x
2026-10-13S2
Wk 7 · Vol 1.16x
2026-10-12S2
Wk 7 · Vol 0.94x
2026-10-09S2
Wk 7 · Vol 0.37x
2026-10-08S2
Wk 7 · Vol 0.42x
2026-10-07S2
Wk 6 · Vol 0.70x
Moving averages & range
50 DMA
$2.04
200 DMA
$1.65
52W High
$2.60
52W Low
$1.17
5D Low
$1.75
Resistance levels (recent highs)
20d High
$1.98
60d High
$2.50
120d High
$2.50
250d High
$2.60
Next resistance
+5.3%
to 20d High
ROE
-88.9%
Profit margin -55.0%
Dividend Yield
0.00%
P/B 2.1

Pulmonx: quick answers

What stage is Pulmonx in?

As of Oct 22, 2026, Pulmonx (LUNG) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 26, 2026 and is in week 9. What the four stages mean

Is Pulmonx in an uptrend?

Yes. Pulmonx is in a Stage 2 uptrend. It trades 14.3% above its 200-day average, which is falling.

How far is Pulmonx from its 52-week high?

Pulmonx closed at $1.88 on Oct 22, 2026, 27.7% below its 52-week high of $2.60. Its 52-week low is $1.17.

How has Pulmonx performed over the past year?

As of Oct 22, 2026, Pulmonx is up 16.8% over the past year and down 18.3% so far in 2026.

Which sector and industry is Pulmonx in?

Pulmonx is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.